ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Jun 2023
Last Updated on 01 Jun 2023
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:

  • Secukinumab 150 mg/mL solution for injection in prefilled pen for treating adults with active non-radiographic axial spondyloarthritis

Funding status

Secukinumab 150 mg/mL solution for injection in prefilled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.

Secukinumab should be used in line with additional clinical criteria for initial and continuing prescriptions for adult patients with active non-radiographic axial spondyloarthritis.

MAF assistance does not apply to ixekizumab, or any other formulations or strengths of secukinumab.


Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis (Published 1 June 2023) PES Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis (Published 1 June 2023)